Tazeen Ahmad
Stock Analyst at B of A Securities
(3.44)
# 925
Out of 5,147 analysts
219
Total ratings
49.38%
Success rate
3.83%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Buy | $97 → $93 | $68.19 | +36.38% | 20 | Feb 20, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $246 → $260 | $233.50 | +11.35% | 12 | Jan 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $529 → $462 | $332.92 | +38.77% | 7 | Jan 30, 2026 | |
| BLTE Belite Bio | Initiates: Buy | $195 | $190.30 | +2.47% | 1 | Jan 26, 2026 | |
| APLS Apellis Pharmaceuticals | Upgrades: Buy | $28 | $20.96 | +33.59% | 10 | Jan 21, 2026 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Buy | $627 → $860 | $781.67 | +10.02% | 1 | Jan 7, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $72 → $58 | $23.39 | +147.97% | 7 | Jan 2, 2026 | |
| FULC Fulcrum Therapeutics | Maintains: Underperform | $6 → $7 | $8.38 | -16.47% | 7 | Dec 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $71 → $112 | $91.35 | +22.61% | 1 | Dec 9, 2025 | |
| PHVS Pharvaris | Maintains: Neutral | $27 → $30 | $28.39 | +5.67% | 5 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $53 | $44.27 | +19.72% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $104 | $101.27 | +2.70% | 6 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $880 → $887 | $766.92 | +15.66% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $16 | $16.76 | -4.53% | 26 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $27 | $24.56 | +9.93% | 16 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $134 | $110.23 | +21.56% | 9 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.53 | +76.60% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $95 | $92.73 | +2.45% | 9 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $8.75 | +71.43% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $8.67 | -53.86% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $20.47 | -60.92% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $21.18 | +27.48% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $13.27 | +111.00% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $9.66 | +314.08% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $132.25 | +35.35% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $16.28 | +35.14% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $6.22 | -51.77% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $14.37 | +4.38% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $5.60 | +78.57% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.48 | +305.41% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $8.94 | +67.79% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $4.10 | -51.22% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $2.76 | +117.39% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $27.80 | -46.04% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $336.75 | -82.18% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.47 | +988.44% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $156.59 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $20.99 | +1,329.25% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.17 | +314.75% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $21.91 | +119.08% | 6 | Oct 10, 2018 |
PTC Therapeutics
Feb 20, 2026
Maintains: Buy
Price Target: $97 → $93
Current: $68.19
Upside: +36.38%
Ascendis Pharma
Jan 30, 2026
Maintains: Buy
Price Target: $246 → $260
Current: $233.50
Upside: +11.35%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Buy
Price Target: $529 → $462
Current: $332.92
Upside: +38.77%
Belite Bio
Jan 26, 2026
Initiates: Buy
Price Target: $195
Current: $190.30
Upside: +2.47%
Apellis Pharmaceuticals
Jan 21, 2026
Upgrades: Buy
Price Target: $28
Current: $20.96
Upside: +33.59%
Regeneron Pharmaceuticals
Jan 7, 2026
Upgrades: Buy
Price Target: $627 → $860
Current: $781.67
Upside: +10.02%
Ultragenyx Pharmaceutical
Jan 2, 2026
Maintains: Buy
Price Target: $72 → $58
Current: $23.39
Upside: +147.97%
Fulcrum Therapeutics
Dec 9, 2025
Maintains: Underperform
Price Target: $6 → $7
Current: $8.38
Upside: -16.47%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $71 → $112
Current: $91.35
Upside: +22.61%
Pharvaris
Dec 4, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $28.39
Upside: +5.67%
Oct 9, 2025
Initiates: Buy
Price Target: $53
Current: $44.27
Upside: +19.72%
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $101.27
Upside: +2.70%
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $766.92
Upside: +15.66%
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $16.76
Upside: -4.53%
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $27
Current: $24.56
Upside: +9.93%
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $110.23
Upside: +21.56%
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $4.53
Upside: +76.60%
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $92.73
Upside: +2.45%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $8.75
Upside: +71.43%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $8.67
Upside: -53.86%
May 19, 2025
Maintains: Underperform
Price Target: $10 → $8
Current: $20.47
Upside: -60.92%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $21.18
Upside: +27.48%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $13.27
Upside: +111.00%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $9.66
Upside: +314.08%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $132.25
Upside: +35.35%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $16.28
Upside: +35.14%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $6.22
Upside: -51.77%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $14.37
Upside: +4.38%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $5.60
Upside: +78.57%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.48
Upside: +305.41%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $8.94
Upside: +67.79%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $4.10
Upside: -51.22%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $2.76
Upside: +117.39%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $27.80
Upside: -46.04%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $336.75
Upside: -82.18%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.47
Upside: +988.44%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $156.59
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $20.99
Upside: +1,329.25%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.17
Upside: +314.75%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $21.91
Upside: +119.08%